Harrow announced an expansion of its Vevye Access for All (“VAFA”) program to include patients currently prescribed Klarity-C Drops, a compounded cyclosporine 0.1% product manufactured and distributed by ImprimisRx, Harrow’s compounding subsidiary. Since its launch on March 17, 2025, Vevye Access for All has simplified dry eye therapy for eligible patients by eliminating access barriers such as prior authorization and reimbursement delays, providing free home delivery, and offering a no‑questions-asked, money-back guarantee,1 the company said in a press release.
According to , the Vevye Access for All program is flexible, allowing patients to choose to use their insurance coverage2 or take advantage of Harrow’s affordable cash price.
As a result of today’s announcement, beginning immediately, Harrow said that more than 25,000 patients across the United States will be able to convert their Klarity-C prescriptions to Vevye (cyclosporine ophthalmic solution) 0.1%, an FDA‑approved treatment for the signs and symptoms of dry eye disease, for $59 per bottle (including refills). As a part of this transition, Klarity-C prescribers have access to a prescription authorization platform to transfer Klarity-C prescriptions to PhilRx in a process that shouldn’t take more than 5 minutes, the company said.
“The secret to the success of Vevye Access for All is simple: lower costs to patients and eliminate the requirement for prescribers to endure the burden of access obstacles like prior authorizations and step therapy," said Mark L. Baum, chief executive officer of Harrow, in the press release. "The result is twofold: dry eye patients receive what their doctor prescribes at an affordable price; and for doctors and their staff, choosing Vevye is an absolute no‑brainer.”
According to Harrow, Klarity-C prescribers who have questions regarding the transition to Vevye or the Vevye Access for All program may call (855) 977-0975 or e-mail mdsupport@usephil.com for further assistance.
1. This offer is available on one fill only and is valid only for eligible patients paying cash who do not have commercial or government insurance. This offer is not valid for patients with government insurance, including, but not limited to, Medicaid or Medicare. Contact Harrow at 833-443-7769 for information on our money-back guarantee.
2. For patients whose prescriptions are covered by commercial insurance, use of this program may reduce their Vevye copayment to as little as $0. For patients whose prescriptions are not covered by commercial insurance, this program may reduce their cost for prescriptions to as little as $59. For full terms and conditions, please visit vevye.com/accessforall.